Education
About Us
Working with TipRanks
Follow Us
TScan Therapeutics (TCRX)
NASDAQ:TCRX
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 2.82M | $ 21.05M | $ 13.54M | $ 10.14M | $ 1.08M |
| Gross Profit | $ 2.82M | $ -67.10M | $ 8.40M | $ 6.81M | $ -19.49M |
| Operating Income | $ -134.82M | $ -93.46M | $ -66.64M | $ -48.64M | $ -26.23M |
| EBITDA | $ -119.74M | $ -80.10M | $ -59.91M | $ -45.30M | $ -25.00M |
| Net Income | $ -127.50M | $ -89.22M | $ -65.81M | $ -48.63M | $ -26.02M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 290.11M | $ 192.04M | $ 120.03M | $ 161.41M | $ 34.79M |
| Total Assets | $ 371.12M | $ 272.15M | $ 199.09M | $ 188.11M | $ 49.74M |
| Total Debt | $ 97.38M | $ 92.43M | $ 85.98M | $ 6.04M | $ 7.43M |
| Net Debt | $ -81.31M | $ -40.93M | $ -34.04M | $ -155.36M | $ -27.36M |
| Total Liabilities | $ 130.15M | $ 121.28M | $ 99.66M | $ 27.33M | $ 92.20M |
| Stockholders' Equity | $ 240.97M | $ 150.87M | $ 99.43M | $ 160.78M | $ -42.46M |
| Cash Flow | |||||
| Free Cash Flow | $ -114.65M | $ -64.50M | $ -70.73M | $ -58.62M | $ -7.26M |
| Operating Cash Flow | $ -110.82M | $ -61.36M | $ -66.50M | $ -48.68M | $ -3.02M |
| Investing Cash Flow | $ -52.61M | $ -60.76M | $ -4.22M | $ -9.94M | $ -4.24M |
| Financing Cash Flow | $ 208.76M | $ 135.44M | $ 29.36M | $ 189.67M | $ 288.00K |